# Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Final Printed Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>EA/FONSI</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/ Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative Document(s)</td>
<td></td>
</tr>
<tr>
<td>Correspondence</td>
<td>X</td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 17-105/S-070

APPROVAL LETTER
NDA 17-105/SLR-070

Ovation Pharmaceuticals, Inc.
Attention: Gary Gordon, M.D., Ph.D.
Vice President, Clinical Affairs
4 Parkway North, Suite 200
Deerfield, IL 60015

Dear Dr. Gordon:

Please refer to your supplemental new drug application dated November 14, 2002, received November 15, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Tranxene® T and SD (clorazepate dipotassium) Tablets.

This supplemental new drug application provides for the addition of a geriatric use subsection to the PRECAUTIONS section of the package insert in accordance with 21 CFR 201.57(f)(10).

We also refer to your February 13, 2003, commitment to revise the storage statement to read: ‘Protect from moisture. Keep bottle tightly closed. Store below 77° F (25° C). Dispense in a USP tight, light-resistant container.’

We have completed the review of this supplemental application, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the submitted draft labeling dated November 14, 2002, and the additional changes to the DOSAGE AND ADMINISTRATION section that you have committed to above. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted labeling (text for the package insert) with the agreed upon labeling changes cited above.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 17-105/S-070" Approval of this submission by FDA is not required before the labeling is used.
We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you should have any questions, please call Ms. Anna Marie H. Weikel, R.Ph., Senior Regulatory Health Project Manager, at (301) 594-5535.

Sincerely,

[See appended electronic signature page]

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
-------------------
Russell Katz
3/13/03 10:56:49 AM
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 17-105/S-070

FINAL PRINTED LABELING
New: December, 2002

TRANXENE® T-TAB Tablets
CLORAZEPATE DIPOTASSIUM (Nos. 301,302,303)
TRANXENE®-SD & (Nos. 405, 404)
TRANXENE®-SD HALF STRENGTH
CLORAZEPATE DIPOTASSIUM
SINGLE DOSE TABLETS

DESCRIPTION
Chemically, TRANXENE is a benzodiazepine. The empirical formula is
C_{16}H_{11}ClK_{2}N_{2}O_{4}; the molecular weight is 408.92; and the structural formula may be
represented as follows:

\[ \text{The compound occurs as a fine, light yellow, practically odorless powder. It is}
\text{insoluble in the common organic solvents, but very soluble in water. Aqueous solutions}
\text{are unstable, clear, light yellow, and alkaline.}
\]

TRANXENE T-TAB tablets contain either 3.75 mg, 7.5 mg or 15 mg of
clorazepate dipotassium for oral administration. TRANXENE-SD and TRANXENE-SD
HALF STRENGTH tablets contain 22.5 mg and 11.25 mg of clorazepate dipotassium
respectively. TRANXENE-SD and TRANXENE-SD HALF STRENGTH tablets
gradually release clorazepate and are designed for once-a-day administration in patients
already stabilized on TRANXENE T-TAB tablets.

Inactive ingredients for TRANXENE T-TAB® Tablets: Colloidal silicon dioxide,
FD&C Blue No. 2 (3.75 mg only), FD&C Yellow No. 6 (7.5 mg only), FD&C Red No. 3
(15 mg only), magnesium oxide, magnesium stearate, microcrystalline cellulose,
potassium carbonate, potassium chloride, and talc. Inactive ingredients for TRANXENE-
SD and TRANXENE-SD HALF STRENGTH Tablets: Castor oil wax, FD&C Blue No. 2
(SD Half Strength, 11.25 mg only), iron oxide (SD, 22.5 mg only), lactose, magnesium
oxide, magnesium stearate, potassium carbonate, potassium chloride, and talc.

CLINICAL PHARMACOLOGY
Pharmacologically, clorazepate dipotassium has the characteristics of the
benzodiazepines. It has depressant effects on the central nervous system. The primary
metabolite, nordiazepam, quickly appears in the bloodstream. The serum half-life is about 2 days. The drug is metabolized in the liver and excreted primarily in the urine.

Studies in healthy men have shown that clorazepate dipotassium has depressant effects on the central nervous system. Prolonged administration of single daily doses as high as 120 mg was without toxic effects. Abrupt cessation of high doses was followed in some patients by nervousness, insomnia, irritability, diarrhea, muscle aches, or memory impairment.

Since orally administered clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, there is essentially no circulating parent drug. Nordiazepam, the primary metabolite, quickly appears in the blood and is eliminated from the plasma with an apparent half-life of about 40 to 50 hours. Plasma levels of nordiazepam increase proportionally with TRANXENE dose and show moderate accumulation with repeated administration. The protein binding of nordiazepam in plasma is high (97-98%).

Within 10 days after oral administration of a 15 mg (50μCi) dose of ¹⁴C-TRANXENE to two volunteers, 62-67% of the radioactivity was excreted in the urine and 15-19% was eliminated in the feces. Both subjects were still excreting measurable amounts of radioactivity in the urine (about 1% of the ¹⁴C-dose) on day ten.

Nordiazepam is further metabolized by hydroxylation. The major urinary metabolite is conjugated oxazepam (3-hydroxynordiazepam), and smaller amounts of conjugated p-hydroxynordiazepam and nordiazepam are also found in the urine.

INDICATIONS AND USAGE
TRANXENE is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.

TRANXENE tablets are indicated as adjunctive therapy in the management of partial seizures.

The effectiveness of TRANXENE tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient.

TRANXENE tablets are indicated for the symptomatic relief of acute alcohol withdrawal.

CONTRAINDICATIONS
TRANXENE tablets are contraindicated in patients with a known hypersensitivity to the drug and in those with acute narrow angle glaucoma.

WARNINGS
TRANXENE tablets are not recommended for use in depressive neuroses or in psychotic reactions.

Patients taking TRANXENE tablets should be cautioned against engaging in hazardous occupations requiring mental alertness, such as operating dangerous machinery including motor vehicles.
Since TRANXENE has a central nervous system depressant effect, patients should be advised against the simultaneous use of other CNS-depressant drugs, and cautioned that the effects of alcohol may be increased.

Because of the lack of sufficient clinical experience, TRANXENE tablets are not recommended for use in patients less than 9 years of age.

Physical and Psychological Dependence:
Withdrawal symptoms (similar in character to those noted with barbiturates and alcohol) have occurred following abrupt discontinuance of clorazepate. Withdrawal symptoms associated with the abrupt discontinuation of benzodiazepines have included convulsions, delirium, tremor, abdominal and muscle cramps, vomiting, sweating, nervousness, insomnia, irritability, diarrhea, and memory impairment. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation of clorazepate should generally be avoided and a gradual dosage tapering schedule followed.

Caution should be observed in patients who are considered to have a psychological potential for drug dependence.

Evidence of drug dependence has been observed in dogs and rabbits which was characterized by convulsive seizures when the drug was abruptly withdrawn or the dose was reduced; the syndrome in dogs could be abolished by administration of clorazepate.

Usage in Pregnancy:
An increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam, and meprobamate) during the first trimester of pregnancy has been suggested in several studies. Clorazepate dipotassium, a benzodiazepine derivative, has not been studied adequately to determine whether it, too, may be associated with an increased risk of fetal abnormality. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy or intend to become pregnant they should communicate with their physician about the desirability of discontinuing the drug.

Usage during Lactation:
TRANXENE tablets should not be given to nursing mothers since it has been reported that nordiazepam is excreted in human breast milk.

PRECAUTIONS
In those patients in which a degree of depression accompanies the anxiety, suicidal tendencies may be present and protective measures may be required. The least amount of drug that is feasible should be available to the patient.
Patients taking TRANXENE tablets for prolonged periods should have blood counts and liver function tests periodically. The usual precautions in treating patients with impaired renal or hepatic function should also be observed.

In elderly or debilitated patients, the initial dose should be small, and increments should be made gradually, in accordance with the response of the patient, to preclude ataxia or excessive sedation.

*Information for Patients:*
To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical dependence, it is essential that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.

*Pediatric Use:* See **WARNINGS.**

*Geriatric Use:* Clinical studies of Tranxene were not adequate to determine whether subjects aged 65 and over respond differently than younger subjects. Elderly or debilitated patients may be especially sensitive to the effects of all benzodiazepines, including Tranxene. In general, elderly or debilitated patients should be started on lower doses of Tranxene and observed closely, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Dose adjustments should also be made slowly, and with more caution in this patient population (see **PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**).

**ADVERSE REACTIONS**
The side effect most frequently reported was drowsiness. Less commonly reported (in descending order of occurrence) were: dizziness, various gastrointestinal complaints, nervousness, blurred vision, dry mouth, headache, and mental confusion. Other side effects included insomnia, transient skin rashes, fatigue, ataxia, genitourinary complaints, irritability, diplopia, depression, tremor, and slurred speech.

There have been reports of abnormal liver and kidney function tests and of decrease in hematocrit.

Decrease in systolic blood pressure has been observed.

**DOSAGE AND ADMINISTRATION**
*For the symptomatic relief of anxiety:*

TRANXENE T-TAB® tablets are administered orally in divided doses. The usual daily dose is 30 mg. The dose should be adjusted gradually within the range of 15 to 60 mg daily in accordance with the response of the patient. In elderly or debilitated patients it is advisable to initiate treatment at a daily dose of 7.5 to 15 mg.

TRANXENE tablets may also be administered in a single dose daily at bedtime; the recommended initial dose is 15 mg. After the initial dose, the response of the patient may require adjustment of subsequent dosage. Lower doses may be indicated in the elderly patient. Drowsiness may occur at the initiation of treatment and with dosage increment.

TRANXENE-SD (22.5 mg) tablets may be administered as a single dose every 24 hours. This tablet is intended as an alternate dosage form for the convenience of patients.
stabilized on a dose of 7.5 mg tablets three times a day. TRANXENE-SD tablets should not be used to initiate therapy.

TRANXENE-SD HALF STRENGTH (11.25 mg) tablets may be administered as a single dose every 24 hours. This tablet is intended as an alternate dosage form for the convenience of patients stabilized on a dose of 3.75 mg tablets three times a day. TRANXENE-SD HALF STRENGTH should not be used to initiate therapy.

For the symptomatic relief of acute alcohol withdrawal:
The following dosage schedule is recommended:

<table>
<thead>
<tr>
<th>Period</th>
<th>Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st 24 hours</td>
<td>30 mg initially; followed by 30 to 60 mg in divided doses</td>
</tr>
<tr>
<td>(Day 1)</td>
<td></td>
</tr>
<tr>
<td>2nd 24 hours</td>
<td>45 to 90 mg in divided doses</td>
</tr>
<tr>
<td>(Day 2)</td>
<td></td>
</tr>
<tr>
<td>3rd 24 hours</td>
<td>22.5 to 45 mg in divided doses</td>
</tr>
<tr>
<td>(Day 3)</td>
<td></td>
</tr>
<tr>
<td>Day 4</td>
<td>15 to 30 mg in divided doses</td>
</tr>
</tbody>
</table>

Thereafter, gradually reduce the daily dose to 7.5 to 15 mg. Discontinue drug therapy as soon as patient's condition is stable.

The maximum recommended total daily dose is 90 mg. Avoid excessive reductions in the total amount of drug administered on successive days.

As an Adjunct to Antiepileptic Drugs:
In order to minimize drowsiness, the recommended initial dosages and dosage increments should not be exceeded.

Adults: The maximum recommended initial dose in patients over 12 years old is 7.5 mg three times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 90 mg/day.

Children (9-12 years): The maximum recommended initial dose is 7.5 mg two times a day. Dosage should be increased by no more than 7.5 mg every week and should not exceed 60 mg/day.

**DRUG INTERACTIONS**

If TRANXENE is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition. Clinical studies have shown increased sedation with concurrent hypnotic medications. The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.

If TRANXENE tablets are used to treat anxiety associated with somatic disease states, careful attention must be paid to possible drug interaction with concomitant medication.

In bioavailability studies with normal subjects, the concurrent administration of antacids at therapeutic levels did not significantly influence the bioavailability of TRANXENE tablets.
OVERDOSAGE
Overdosage is usually manifested by varying degrees of CNS depression ranging from slight sedation to coma. As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.

The treatment of overdosage should consist of the general measures employed in the management of overdosage of any CNS depressant. Gastric evacuation either by the induction of emesis, lavage, or both, should be performed immediately. General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated. Hypotension, though rarely reported, may occur with large overdoses. In such cases the use of agents such as Levophed® Bitartrate (norepinephrine bitartrate injection, USP) or Aramine® Injection (metaraminol bitartrate injection, USP) should be considered.

While reports indicate that individuals have survived overdoses of clorazepate dipotassium as high as 450 to 675 mg, these doses are not necessarily an accurate indication of the amount of drug absorbed since the time interval between ingestion and the institution of treatment was not always known. Sedation in varying degrees was the most common physiological manifestation of clorazepate dipotassium overdose. Deep coma when it occurred was usually associated with the ingestion of other drugs in addition to clorazepate dipotassium.

Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an overdose with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine overdose. Patients treated with flumazenil should be monitored for reedation, respiratory depression, and other residual benzodiazepine effects for an appropriate period after treatment. The prescriber should be aware of a risk of seizure in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant overdose. The complete flumazenil package insert including CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS should be consulted prior to use.

ANIMAL PHARMACOLOGY AND TOXICOLOGY
Studies in rats and monkeys have shown a substantial difference between doses producing tranquilizing, sedative and toxic effects. In rats, conditioned avoidance response was inhibited at an oral dose of 10 mg/kg; sedation was induced at 32 mg/kg; the LD₅₀ was 1320 mg/kg. In monkeys aggressive behavior was reduced at an oral dose of 0.25 mg/kg; sedation (ataxia) was induced at 7.5 mg/kg; the LD₅₀ could not be determined because of the emetic effect of large doses, but the LD₅₀ exceeds 1600 mg/kg.

Twenty-four dogs were given clorazepate dipotassium orally in a 22-month toxicity study; doses up to 75 mg/kg were given. Drug-related changes occurred in the liver; weight was increased and cholestasis with minimal hepatocellular damage was found, but lobular architecture remained well preserved.

Eighteen rhesus monkeys were given oral doses of clorazepate dipotassium from 3 to 36 mg/kg daily for 52 weeks. All treated animals remained similar to control
animals. Although total leucocyte count remained within normal limits it tended to fall in the female animals on the highest doses.

Examination of all organs revealed no alterations attributable to clorazepate dipotassium. There was no damage to liver function or structure.

Reproduction Studies:
Standard fertility, reproduction, and teratology studies were conducted in rats and rabbits. Oral doses in rats up to 150 mg/kg and in rabbits up to 15 mg/kg produced no abnormalities in the fetuses. TRANXENE did not alter the fertility indices or reproductive capacity of adult animals. As expected, the sedative effect of high doses interfered with care of the young by their mothers (see Usage in Pregnancy).

HOW SUPPLIED
TRANXENE® 3.75 mg, scored T-TAB tablets are supplied as blue-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 31. Bottles of 100 ......................... (NDC 67386-301-01)

7.5 mg scored T-TAB tablets are supplied as peach-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 32. Bottles of 100 ......................... (NDC 67386-302-01)
Bottles of 500 ......................... (NDC 67386-302-05)
15 mg scored T-TAB tablets are supplied as lavender-colored tablets bearing the letters OV, the distinctive T shape and a two-digit designation, 33.
Bottles of 100 ........................................ (NDC 67386-303-01)

TRANXENE®-SD 22.5 mg single dose tablets are supplied as tan-colored tablets bearing the letters OV and a two-digit designation, 45.
Bottles of 100 ........................................ (NDC 67386-405-01)

TRANXENE®-SD HALF STRENGTH 11.25 mg single dose tablets are supplied as blue-colored tablets bearing the letters OV and a two-digit designation, 44.
Bottles of 100 ........................................ (NDC 67386-404-01)

Protect from moisture. Keep bottle tightly closed.
Store below 77°F (25°C).
Dispense in a USP tight, light-resistant container.
T-TAB, tablet appearance and shape are registered trademarks of Ovation Pharmaceuticals. U.S. Design Pat. No. D-300,879
®Registered trademark of Ovation Pharmaceuticals, Inc.

Manufactured by Abbott Laboratories, North Chicago, Illinois, 60064 for:

OVATION PHARMACEUTICALS, INC.
Deerfield, Illinois 60015 U.S.A.

December 2002
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 17-105/S-070

MEDICAL REVIEW
REVIEW AND EVALUATION OF CLINICAL DATA

NDA: 17-105
Sponsor: Ovation Pharmaceuticals
Drug: Tranxene®, clorazepate dipotassium
Indication: Management of anxiety, adjunctive treatment partial seizures, acute alcohol withdrawal.
Dates of Submission: November 14, 2002
Materials Reviewed: Draft changes being effected labeling supplement (CBE) SLR-070 Geriatric Labeling Supplement

Background
Tranxene is a long-acting benzodiazepine that has a history of many medical uses. The sponsor proposes a GERAITRIC USE labeling section based on the sponsor's review of the current literature pertaining to safety and pharmacokinetic.

Draft Labeling Review
The proposed Geriatric Use section is based on a review of the literature. I replicated the sponsor's literature MEDLINE search. Desmethyl Diazepam (DMDZ) a major active metabolite had significantly lower clearance in older men but not in women (Shader, Greenblatt et al. 1981); however, the variability of the DMDZ clearance was so great that few conclusions can be drawn from this study. Nonetheless, self-rated sedation decreased with decreasing parent drug plasma levels and did not correlate with DMDZ levels in another study (Greenblatt, Shader et al. 1979). This is an interesting finding given that DMDZ is considered the active ingredient in the CLINICAL PHARMACOLOGY section of product labeling. A naturalistic study of Tranxene® use in elderly patients with moderately severe atherosclerotic disease reported that Tranxene® was well tolerated and effective in reducing "hypochondria, hysteroidness, psychoasthenic, and depression" (Grebelnik 1995).

There were two reported cases of toxicity due to DMDZ in patients with impaired liver function. These patients required critical care support and constant flumazenil infusion to avoid respiratory arrest (Guglielminotti, Maury et al. 1999). Current labeling does not mention these cases per se; however, the PRECAUTIONS section suggests that liver function tests should be monitored and that caution should be used when prescribing Tranxene® to patients with hepatic and renal impairment.

Conclusions
The suggestions in the Geriatric Use labeling section are appropriate. I recommend that the Division take an approval action on this supplement.
Paul J. Andreason, MD
Medical Reviewer, CDER, DNDP, HFD-120

Cc:
P Andreason
T Laughren
AM Hommanay

References


This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
Paul Andreason  
12/3/02 04:09:37 PM  
MEDICAL OFFICER

Thomas Laughren  
12/4/02 08:36:12 AM  
MEDICAL OFFICER
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 17-105/S-070

CORRESPONDENCE
NDA 17-105/SLR-070

Ovation Pharmaceuticals, Inc.
Attention: Gary Gordon, M.D., Ph.D.
Vice-President Clinical Affairs
1 Overlook Point, Suite 110
Lincolnshire, IL 60069

Dear Dr. Gordon:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Tranxene® (clorazepate dipotassium) Tablets

NDA Number: 17-105

Supplement Number: SLR-070

Date of Supplement: November 14, 2002

Date of Receipt: November 15, 2002

This supplement proposes the addition of a ‘Geriatric Use’ subsection to the ‘Precautions’ section of the labeling.

Unless we notify you within 60 days of our receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on January 15, 2003, in accordance with 21 CFR 314.101(a).

Please cite the application number listed above at the top of the first page of any communications concerning this application. All communications concerning this supplemental application should be addressed as follows:
U.S. Postal Service:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Neuropharmacological Drug Products, HFD-120
Attention: Division Document Room 4008
5600 Fishers Lane
Rockville, Maryland 20857

Courier/Overnight Mail:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Neuropharmacological Drug Products, HFD-120
Attention: Division Document Room 4008
1451 Rockville Pike
Rockville, Maryland 20852-1420

If you should have any questions, please call Ms. Anna Marie H. Weikel, R.Ph., Regulatory Affairs Manager, at (301) 594-5535.

Sincerely,

[See appended electronic signature page]

Robbin Nighswander, R.Ph.
Chief, Project Management Staff
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Anna-Marie Homonnay
11/21/02 11:14:06 AM